



**HAL**  
open science

## Prevalence of extended-spectrum beta-lactamase producing *Escherichia coli* in community-onset urinary tract infections in France in 2013

D. Martin, S. Fougnot, F. Grobost, S. Thibaut-Jovelin, F. Ballereau, T. Gueudet, D. de Mouy, Jérôme Robert

### ► To cite this version:

D. Martin, S. Fougnot, F. Grobost, S. Thibaut-Jovelin, F. Ballereau, et al.. Prevalence of extended-spectrum beta-lactamase producing *Escherichia coli* in community-onset urinary tract infections in France in 2013. *Journal of Infection*, 2015, 72 (2), pp.201-206. 10.1016/j.jinf.2015.11.009 . hal-01246265

**HAL Id: hal-01246265**

<https://hal.sorbonne-universite.fr/hal-01246265v1>

Submitted on 18 Dec 2015

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1           **Prevalence of extended-spectrum beta-lactamase producing *Escherichia coli* in**  
2                           **community-onset urinary tract infections in France in 2013**

3   D. Martin<sup>1</sup>, S. Fougnot<sup>2</sup>, F. Grobost<sup>1,3</sup>, S. Thibaut-Jovelin<sup>4</sup>, F. Ballereau<sup>4</sup>, T. Gueudet<sup>1,5</sup>, D. de  
4   Mouy<sup>1,6</sup>, J. Robert<sup>1,7</sup>, on behalf of ONERBA-ville network

5  
6   <sup>1</sup> Observatoire National de l'Epidémiologie de la Résistance Bactérienne aux Antibiotiques  
7   (ONERBA), Paris, France

8   <sup>2</sup> BPR Network, Laboratoire Atoutbio, Nancy, France

9   <sup>3</sup> EPIVILLE Network, Laboratoire d'Analyses Médicales, La Ferté Bernard, France

10   <sup>4</sup> MedQual-Ville Network, Hôpital Saint-Jacques, CHU de Nantes, Nantes, France

11   <sup>5</sup> EPIVILLE Network, Laboratoire Schuh BIO67, Strasbourg, France

12   <sup>6</sup> AFORCOPI-BIO network, LABM Claude-Bernard, Paris, France

13   <sup>7</sup> Sorbonne Universités, UPMC Univ Paris 06, CR7, INSERM U1135, Centre d'Immunologie  
14   et des Maladies Infectieuses, CIMI, team E13 (Bacteriology), AP-HP Hôpitaux Universitaires  
15   Pitié Salpêtrière – Charles Foix, Bacteriology and Hygiene, F-75013, Paris, France

16  
17   Running title: ESBL-positive *E. coli* in UTI in France

18   \* **Corresponding Author:** Jérôme ROBERT

19                           Laboratoire de Bactériologie-Hygiène

20                           Faculté de Médecine Pierre et Marie Curie (UPMC Paris 6),

21                           91 Boulevard de l'hôpital

22                           75634 Paris Cedex 13, France

23                           Tel: (33) 1 40 77 97 49

24                           Fax: (33) 1 45 82 75 77

25                           E-mail: jerome.robert@psl.aphp.fr

26   Word count: 1997

27   Key words: *Escherichia coli*, ESBL, urinary-tract infection, community, fosfomycin,  
28   nitrofurantoin, *Klebsiella pneumoniae*

1 **Abstract**

2 **Objectives.** We sought to assess the importance of extended-spectrum beta-lactamase (ESBL)  
3 producing Enterobacteriaceae in urinary tract infections in outpatients in France.

4 **Methods.** Retrospective laboratory based survey analysing susceptibility patterns of  
5 *Escherichia coli* and *Klebsiella pneumoniae* isolates providing from urines collected from  
6 outpatients during three months in 2013.

7 **Results.** 499 laboratories collected data on 51,643 *E. coli* and 3,495 *K. pneumoniae* isolates.  
8 The overall proportion of ESBL-producing *E. coli* was 3.3%. The proportion was higher for  
9 males (4.8%) than for females (3.0%) and increased with age: 2% for patients <20 years to  
10 5.4% for those aged >80 years. More than 95% of isolates were susceptible to cefixime,  
11 fosfomycin, and nitrofurantoin. In nursing homes, the ESBL-producing *E. coli* proportion was  
12 12.1%. For *K. pneumoniae*, the proportion of ESBL-positive isolates was 6.6%, and this  
13 proportion increased with age. Data from 2010 collected from a subset of the network showed  
14 that the ESBL-producing *E. coli* proportion was 2.0%.

15 **Conclusion.** ESBL-producing isolates were rather frequent in urines in French outpatients in  
16 2013. Males and persons residing in nursing homes were at higher risk of ESBL-positive  
17 infection. Despite the increase in ESBL-positive isolates, the susceptibility to antibiotics used  
18 to treat cystitis remains high.

19

20

## 21 Introduction

22 The worldwide rise of antimicrobial resistance conducted many countries to develop  
23 national plans to control this public health threat.[1,2] After promising results of its first plans,  
24 France is currently in the middle of its third antibiotic sparing plan.[3] In a majority of these  
25 plans, surveillance of antibiotic resistance is recognised as a core issue. The goals for such  
26 surveillance have been listed elsewhere. [4] In particular, surveillance data should help in  
27 establishing guidelines for empirical treatment when antibiotic susceptibility tests results are  
28 not yet available or will not be performed. In addition, up-to-date data are of interest to assess  
29 the accuracy of already published guidelines.

30 Urinary tract infections (UTI) are among the most common bacterial infections that  
31 are treated in the community by an empirical antibiotic treatment regimen. In many countries,  
32 it is currently not recommended to perform urinalysis for cystitis before treatment, and the  
33 choice of the antibiotic regimen relies on the epidemiology of antibiotic resistance.  
34 *Escherichia coli*, which is a commensal species of the digestive tract, is the most common  
35 bacterial species isolated in UTI. The increase in resistance of *E. coli* to extended-spectrum  
36 cephalosporins (ESC) is now well documented, and is mainly due to the production of  
37 extended-spectrum beta-lactamase (ESBL) in the hospital setting as well as in the  
38 community.[1,5] In France for instance, there has been a 10-fold increase in the digestive  
39 carriage of ESBL-producing *E. coli* in the community in the last years.[6] The increase in  
40 ESBL-producing *E. coli* makes the treatment of community-onset UTI more complex because  
41 such isolates are usually multidrug-resistant, which increases the risk of treatment  
42 failure.[1,2,7] In addition, treating ESBL-positive infection is more costly than treating their  
43 susceptible counterpart.[7] Therefore, it is of interest to gather up-to-date data on the  
44 prevalence of antibiotic resistance of *E. coli* isolated from UTIs in the community.

45 Our main objective was to assess the prevalence of ESBL-producing *E. coli* amongst  
46 all *E. coli* isolated from urine samples in the community in ambulatory care in 2013. Data on

47 *Klebsiella pneumoniae* the second most frequent Enterobacteriaceae isolated in community-  
48 acquired UTIs and data from patients in nursing homes were also collected for comparison  
49 purposes.

ACCEPTED MANUSCRIPT

## 50 **Materials and methods**

### 51 *Laboratories*

52 Private practice laboratories participating in one of the three pre-existing networks (EpiVille,  
53 MedQual-ville, Aforcopi-Bio) of the national observatory for epidemiology of bacterial  
54 resistance to antibiotics (ONERBA), and to a fourth network previously set-up for other  
55 purposes than surveillance of bacterial resistance (BPR network) were asked to participate on  
56 a voluntary basis. A special attention has been paid to national coverage of the network. A  
57 total of 499 private practice laboratories distributed throughout metropolitan France, and that  
58 referred urines clinical samples to 43 bacteriological centres participated into the network.

59

### 60 *Bacteriology*

61 Laboratories participating in this new network called « ONERBA-Ville » complied with  
62 national recommendations regarding antibiotic susceptibility testing ([www.sfm-](http://www.sfm-microbiologie.org)  
63 [microbiologie.org](http://www.sfm-microbiologie.org)), which are very similar to EUCAST recommendations  
64 ([http://www.eucast.org/ast\\_of\\_bacteria](http://www.eucast.org/ast_of_bacteria)), derived from ONERBA's recommendations for  
65 surveillance of bacterial resistance.[4,8]

66 Antibiotic susceptibility test methods were chosen locally and included liquid media  
67 automated systems (n= 35 for Vitek-2, BioMérieux; n=4 for BD Phoenix system, BD  
68 Biosciences; n=4 for Microscan WalkAway, Siemens Healthcare diagnostics) and the disk  
69 diffusion method (n=6). ESBL-production was determined according to national  
70 recommendations as described elsewhere. [9]

71 Isolates were considered susceptible to tested antibiotics by using the following breakpoints:  
72  $\leq 4/2$  mg/L for amoxicilline/clavulanate,  $\leq 1$  mg/L for cefixime,  $\leq 0.5$  mg/L for ciprofloxacin,  
73  $\leq 32$  mg/L for fosfomicin,  $\leq 64$  mg/L for nitrofurantoin, and  $\leq 2/38$  mg/L for cotrimoxazole.

74

### 75 *Database*

76 Data were retrospectively collected for each *E. coli* or *K. pneumoniae* strain isolated from  
77 urines routinely collected for diagnosis of community-onset urinary tract infections in  
78 outpatients or those in nursing home during September to November 2013. Data included  
79 patient's age, gender, and susceptibility tests results including ESBL production. In case of  
80 duplicates, only the first isolate was retained for the study. Whenever possible and for  
81 comparison purpose, similar data were collected for 2010.

82

### 83 *Data analysis*

84 Data have been analysed by using STATA 11 (StataCorp, College Station, TX, USA).  
85 Fisher's exact test was used to compare proportions. The Chi2 test for trend has been used to  
86 assess the impact of age on the proportion of ESBL-producing isolates. A p-value < 0.05 was  
87 considered as statistically significant.

88

89 **Results**90 *E. coli* isolated from outpatients in 2013

91 Data on 51,463 *E. coli* isolates were collected from urine samples of outpatients during the 3-  
92 month study period. The median age of the patients was 60 years and 86.4% were females.

93 Among all isolates, 1,694 (3.3%) were ESBL-positive. Patients with ESBL-producing isolates  
94 were older (median, 70 years) than those with ESBL-negative isolates (median, 60 years;  
95  $p<0.001$ ). The proportion of ESBL-producing *E. coli* was higher in males (4.8%) than in  
96 females (3.0%,  $p<0.001$ ). The proportion of patients harbouring ESBL-producing isolates  
97 increased with age (Table 1): from 2.0% among patients under 20 years, to 5.4% among those  
98 over 80 years ( $p<0.001$ , chi-square test for trend). This significant trend was observed after  
99 stratified analysis by gender (Table 1).

100 As expected, ESBL-producing isolates were significantly less frequently susceptible to  
101 antibiotics than ESBL-negative isolates: 22.7% against 67.6% for co-amoxiclav, 47.5%  
102 versus 80.8% for cotrimoxazole, 44.0% against 91.0% for ciprofloxacin, 4.0% against 98.0%  
103 for cefixime, 93.7% against 98.9% for fosfomycin, 95.4% against 98.9% for nitrofurantoin  
104 (Table 2). Overall, 6.0% of the isolates were resistant to at least 3 of the 6 drugs.

105 *E. coli* isolated in nursing homes in 2013

106 A subset of 17 technical centres analysing samples for 237 laboratories provided data on 908  
107 *E. coli* isolates from patients located in nursing homes during the study period. The median  
108 age of patients in nursing homes (88 years) was higher than for outpatients (60 years;  
109  $p<0.001$ ). The proportion of ESBL-producing isolates was higher in nursing homes in 2013  
110 (12.1%) than in outpatients (3.3%;  $p<0.001$ ). Of interest, the proportion of ESBL-producing  
111 isolates in nursing homes, did not differ significantly according to gender (14.0% in males  
112 versus 11.7% in females;  $p=0.5$ ). The percentage of susceptibility to ciprofloxacin was lower  
113 for *E. coli* isolated in nursing homes than for those from outpatients for isolates taken as a



114 whole (73.8% versus 89.5%, respectively;  $p < 0.001$ ) or when considering only ESBL-  
115 producing isolates (17.4% versus 44.0%, respectively;  $p < 0.001$ ).

### 116 *K. pneumoniae* isolated from outpatients in 2013

117 A subset of 41 technical centres analysing samples for 493 laboratories provided data on  
118 3,495 *K. pneumoniae* isolates from outpatients. Patients harbouring *K. pneumoniae* were older  
119 than those harbouring *E. coli* (median, 67 versus 60 years;  $p < 0.001$ ), and were more  
120 frequently male (17.8% versus 13.6%;  $p < 0.001$ ). The proportion of ESBL-producing *K.*  
121 *pneumoniae* was 6.6% as compared to 3.3% for *E. coli* ( $p < 0.001$ ). As for *E. coli*, the  
122 proportion of ESBL-producing *K. pneumoniae* was higher among males than females (11.6%  
123 versus 5.6%;  $p < 0.001$ ), and increased with age (Table 1). Regarding antibiotic susceptibility  
124 (Table 2), *K. pneumoniae* isolates were significantly less frequently susceptible than *E. coli*  
125 isolates to cefixime (93.2% versus 95.0%), fosfomycin (74.4% versus 98.7%), and  
126 nitrofurantoin (71.0% versus 98.8%). On the contrary, *K. pneumoniae* isolates were  
127 significantly more susceptible than *E. coli* isolates to ciprofloxacin (91.2% versus 89.5%), and  
128 cotrimoxazole (88.4% versus 79.6%). Overall, 5.9% of the isolates were resistant to at least 3  
129 of the 5 drugs.

130

### 131 *E. coli* isolated from outpatients in 2010

132 A subset of 27 centres analysing samples for 222 laboratories provided data on 15,658 *E. coli*  
133 isolates from outpatients from September to November 2010. The proportion of ESBL-  
134 producing isolates was 2.0% in 2010 as compared to 3.3% in 2013 ( $p < 0.001$ ). The proportion  
135 of ESBL-producing isolates increased with patients' age in 2010, 1.5% before 60 years old to  
136 2.6% in patients over 60 years ( $p < 0.001$ ). Overall, isolates were significantly more susceptible  
137 to cefixime and cotrimoxazole in 2010 (96.5% and 82.9%, respectively) than in 2013 (95.0%  
138 and 79.6%, respectively;  $p < 0.001$  for both comparisons). Isolates were slightly less  
139 susceptible to fosfomycin in 2010 compared to 2013 (97.7% and 98.7%, respectively;

140 p<0.001). The susceptibility to ciprofloxacin and nitrofurantoin was similar in 2010 and 2013.  
141 The susceptibility of ESBL-producing isolates to these antibiotics didn't change between  
142 2010 and 2013.

ACCEPTED MANUSCRIPT

143 **Discussion**

144 We conducted a retrospective survey on the proportion of ESBL-producing *E. coli* and  
145 *K. pneumoniae* isolated from urines of ambulatory or nursing home patients in 2010 and  
146 2013. We showed that the proportion of ESBL-producing isolates was rather high and  
147 increased with age, was higher for males as compared to females and increased since 2010.  
148 Nevertheless, the proportions of susceptible isolates remain elevated for most antibiotics used  
149 in the treatment of uncomplicated *E. coli* UTI.

150 The 3.3% proportion of ESBL-producing *E. coli* in urine samples in France in 2013 is  
151 lower than what was reported in numerous European countries such as Spain (7,6%) Italy,  
152 United-Kingdom and Germany (all circa 6%) between 2008 and 2011.[10–13] On the  
153 opposite, a lower proportion (1.7%) of ESBL-producing *E. coli* was reported from outpatients  
154 in Switzerland in 2009-2010.[14] These differences may be explained by variations in  
155 populations surveyed, use of systematic urinalysis for UTI diagnosis, or by levels of antibiotic  
156 use in the community.[14,15]

157 We report a significant increase in the proportion of ESBL-producing *E. coli* from  
158 2010 to 2013. This is in accordance with previous findings in France showing that the  
159 proportion of ESBL-producing *E. coli* was 0.3% in 1999 and 1.1% in 2006.[5,16] In addition,  
160 during the same period of time, there was a 10-fold increase in the prevalence asymptomatic  
161 carriers of ESBL-producing *E. coli* in the community.[6] However, these studies have been  
162 conducted with different methodologies, and comparisons should be interpreted with caution.  
163 The significant upward trend in ESBL-producing isolates with age as been previously  
164 reported.[17,18] In addition, we confirmed that men have a higher risk of ESBL-positive  
165 infections than women.[18,19] These findings underline the importance of age and gender  
166 stratification for correct interpretation of resistant data and for comparisons between  
167 populations in different settings. It suggests also that guidelines for the treatment of UTI  
168 should be adapted to age and gender.

169 *Antibiotic susceptibility*

170 Despite the rise of ESBL-producing isolates, *E. coli* and *K. pneumoniae* isolates remain  
171 highly susceptible to fosfomicin, and nitrofurantoin, two drugs for which susceptibility rates  
172 were not affected by ESBL production. These data reinforce the 2014 French guidelines for  
173 empirical treatment of uncomplicated UTI, which recommend fosfomicin as first line drug  
174 and nitrofurantoin as an alternative.[20,21] Desperately, we could not gather data regarding  
175 pivmecillinam, which is recommended in the French guidelines. However, a high rate of  
176 clinical failure has been reported recently for the treatment of ESBL-producing isolates with  
177 this drug.[22] We report that 95.0% of all *E. coli* isolates were susceptible to cefixime.  
178 However, this third generation cephalosporin is currently not recommended for the empiric  
179 treatment of simple UTI mainly because of its ecological impact. In addition, the activity of  
180 cefixime is highly susceptible to the production of ESBL, which is now more frequent.

181 *Limitations*

182 Our study has some limitations. First, we collected routine data on urinary samples without  
183 information regarding clinical symptoms and risk factors. This is of importance in the context  
184 of UTI in the community where urinalysis for uncomplicated cystitis is not recommended.  
185 Therefore it is likely that urinalysis was partly performed for the most complicated UTI, and  
186 the observed proportions of ESBL-producing isolates or of antibiotic resistance are likely to  
187 overestimate “true” proportions. However, the observed trend, which is in accordance with  
188 other studies, is likely to be real and calls for actions. The fact that we did not collect risk  
189 factors of antibiotic resistance limits the interpretation of the results. Second, no specific  
190 quality control was organized for the study. However, all French laboratories are now in the  
191 process of national accreditation, which makes mandatory internal and external quality  
192 controls such as the one annually organised by the French Medical Agency.

193 **Conclusion**

194 The retrospective study allowed assessing the magnitude of ESBL-producing isolates in the  
195 outpatients settings. The observed proportion, which is ten times higher than the one observed  
196 15 years ago is worrisome. Such study with a large network has to be repeated to assess trends  
197 over time of antibiotic resistance and the impact of national plans against antibiotic resistance.

198

ACCEPTED MANUSCRIPT

199 **ONERBA-ville Network**

200 F. Alexandre (Moréac), P. Andorin (Laval), F. Artur (Le Havre), H. Banctel (Saint-Brieuc), J.  
201 Bayette (Saint-Thibéry), F. Bonfils (Les Murets), D. Boraud (Le-Haillan), S. Camiade  
202 (Marseille), J. Caillon (Nantes), N. Capron (Coquelles), N. Chatelain (Valenciennes), B.  
203 Coudé du Foresto (Nantes), G. Cous (Bayonne), V. Desroys du Roure (La-Roche-sur-Yon),  
204 H-P. Doermann (Périgueux), A. Dubouix (Toulouse), S. Fougnot (Nancy), J-L. Galinier  
205 (Toulouse), G. Grandjean (Le-Loroux-Bottereau), D. Grisard (Flers), F. Grobost (La Ferté-  
206 Bernard), T. Gueudet (Strasbourg), P. Hance (Marseille), A. Holstein (Chambray-les-Tours),  
207 M-F. Jendrysik (Dunkerque), E. Jobert (Annecy), J-R. Kamdem-Djoko (Les-Herbiers), D.  
208 Lair (Le-Mans), J-M. Le Bris (Lorient), N. Lecordier (Epinal), S. Liébault (Saumur), N.  
209 Lièvre (Saint-Nazaire), J. Nalpas (L'Isle-Adam), G. Payro (Saintes), B. Poirey (Nîmes), E.  
210 Pradier (Caen), L. Prots (Nice), J-P. Rault (Metz), M-L. Roche (Les-Sables-d'Olonne), J.  
211 Thierry (Lyon), H. Valade (Bordeaux), P. Versini (Angers), A. Vrain (Angers), Ph. Weber  
212 (Vaires-sur-Marne)

213

214 **Funding**

215 The study was funded by a special grant from the Direction Générale de la Santé (DGS),  
216 Ministère des Affaires Sociales, de la Santé et des Droits de la Femme.

217

218 **Competing interest**

219 All authors declare no conflict of interest regarding the results of the study

220

221 **References**

222

223 [1] European Centre for Disease Prevention and Control. Antimicrobial resistance  
224 surveillance in Europe 2013. Annual report of the European antimicrobial resistance  
225 surveillance network (EARS-Net). 2014. doi:10.2900/39777.

226

227 [2] World Health Organization. Antimicrobial resistance - Global report on surveillance  
228 2014.  
229 [http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1)  
230 (accessed November 22, 2015).

231

232 [3] Schlemmer B. [Antibiotic sparing campaigns and the French Antibiotic Plan]. *Rev Prat*  
233 2012;62:972–5.

234

235 [4] Cornaglia G, Hryniewicz W, Jarlier V, Kahlmeter G, Mittermayer H, Stratchounski L,  
236 et al. European recommendations for antimicrobial resistance surveillance. *Clin*  
237 *Microbiol Infect* 2004;10:349–83. doi:10.1111/j.1198-743X.2004.00887.x.

238

239 [5] Arpin C, Quentin C, Grobost F, Cambau E, Robert J, Dubois V, et al. Nationwide  
240 survey of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the  
241 French community setting. *J Antimicrob Chemother* 2009;63:1205–14.

242

243 [6] Nicolas-Chanoine M-H, Gruson C, Bialek-Davenet S, Bertrand X, Thomas-Jean F,  
244 Bert F, et al. 10-Fold increase (2006-11) in the rate of healthy subjects with extended-  
245 spectrum  $\beta$ -lactamase-producing *Escherichia coli* faecal carriage in a Parisian check-up  
246 centre. *J Antimicrob Chemother* 2013;68:562–8. doi:10.1093/jac/dks429.

247

248 [7] Esteve-Palau E, Solande G, Sánchez F, Sorlí L, Montero M, Güerri R, et al. Clinical  
249 and economic impact of urinary tract Infections caused by ESBL-producing  
250 *Escherichia coli* requiring hospitalization: a matched cohort study. *J Infect* 2015.  
251 doi:10.1016/j.jinf.2015.08.012.

252

253 [8] Observatoire National l'Epidémiologie de la Résistance Bactérienne aux Antibiotiques  
254 (ONERBA). Recommandations méthodologiques pour la surveillance de la résistance  
255 aux antibiotiques dans les laboratoires de microbiologie ([www.onerba.org](http://www.onerba.org)). vol. 1.  
256 Paris: Edimark S.A. 2000.

257

- 258 [9] Garrec H, Drieux-Rouzet L, Golmard J-L, Jarlier V, Robert J. Comparison of nine  
259 phenotypic methods for detection of Extended-spectrum  $\beta$ -lactamase production by  
260 Enterobacteriaceae. J Clin Microbiol 2011;49:1048–57. doi:10.1128/JCM.02130-10.  
261
- 262 [10] Aguilar-Duran S, Horcajada JP, Sorlí L, Montero M, Salvadó M, Grau S, et al.  
263 Community-onset healthcare-related urinary tract infections: comparison with  
264 community and hospital-acquired urinary tract infections. J Infect 2012;64:478–83.  
265 doi:10.1016/j.jinf.2012.01.010.  
266
- 267 [11] Horner CS, Abberley N, Denton M, Wilcox MH. Surveillance of antibiotic  
268 susceptibility of Enterobacteriaceae isolated from urine samples collected from  
269 community patients in a large metropolitan area, 2010-2012. Epidemiol Infect  
270 2014;142:399–403. doi:10.1017/S0950268813000988.  
271
- 272 [12] Noll I, Schweickert B, Abu Sin M, Feig M, Claus H, Eckmanns T. [Antimicrobial  
273 resistance in Germany. Four years of antimicrobial resistance surveillance (ARS)].  
274 Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012;55:1370–6.  
275 doi:10.1007/s00103-012-1559-3.  
276
- 277 [13] Picozzi S, Ricci C, Gaeta M, Macchi A, Dinang E, Paola G, et al. Do we really know  
278 the prevalence of multi-drug resistant *Escherichia coli* in the territorial and nosocomial  
279 population? Urol Ann 2013;5:25–9. doi:10.4103/0974-7796.106962.  
280
- 281 [14] Kronenberg A, Koenig S, Droz S, Mühlemann K. Active surveillance of antibiotic  
282 resistance prevalence in urinary tract and skin infections in the outpatient setting. Clin  
283 Microbiol Infect 2011;17:1845–51. doi:10.1111/j.1469-0691.2011.03519.x.  
284
- 285 [15] Adriaenssens N, Coenen S, Versporten A, Muller A, Minalu G, Faes C, et al. European  
286 Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in  
287 Europe (1997-2009). J Antimicrob Chemother 2011;66 Suppl 6:vi3–12.  
288 doi:10.1093/jac/dkr453.  
289
- 290 [16] Arpin C, Dubois V, Coulange L, Andre C, Fischer I, Noury P, et al. Extended-spectrum  
291 beta-lactamase-producing Enterobacteriaceae in community and private health care  
292 centers. Antimicrob Agents Chemother 2003;47:3506–14.  
293 doi:10.1128/AAC.47.11.3506-3514.2003.  
294
- 295 [17] Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JDD, Quentin C, Calbo ES, et al. A  
296 multinational survey of risk factors for infection with extended-spectrum beta-  
297 lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis



- 298 2009;49:682–90. doi:10.1086/604713.
- 299
- 300 [18] Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the  
301 development of extended-spectrum beta-lactamase-producing bacteria in  
302 nonhospitalized patients. *Eur J Clin Microbiol Infect Dis* 2004;23:163–7.  
303 doi:10.1007/s10096-003-1084-2.
- 304
- 305 [19] Azap OK, Arslan H, Serefhanoglu K, Colakoglu S, Erdogan H, Timurkaynak F, et al.  
306 Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic  
307 *Escherichia coli* isolated from community-acquired urinary tract infections. *Clin*  
308 *Microbiol Infect* 2010;16:147–51. doi:10.1111/j.1469-0691.2009.02941.x.
- 309
- 310 [20] Société de Pathologie Infectieuse de Langue Française. Diagnostic et antibiothérapie  
311 des infections urinaires bactériennes communautaires de l'adulte. Mise au point 2014.  
312 [http://www.infectiologie.com/UserFiles/File/medias/Recos/2014-infections\\_urinaires-](http://www.infectiologie.com/UserFiles/File/medias/Recos/2014-infections_urinaires-court.pdf)  
313 [court.pdf](http://www.infectiologie.com/UserFiles/File/medias/Recos/2014-infections_urinaires-court.pdf) (accessed November 22, 2015).
- 314
- 315 [21] Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW.  
316 Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. *J*  
317 *Antimicrob Chemother* 2015. doi:10.1093/jac/dkv147.
- 318
- 319 [22] Søråas A, Sundsfjord A, Jørgensen SB, Liestøl K, Jenum PA. High rate of per oral  
320 mecillinam treatment failure in community-acquired urinary tract infections caused by  
321 ESBL-producing *Escherichia coli*. *PLoS One* 2014;9:e85889.  
322 doi:10.1371/journal.pone.0085889.

323

324

325 Table 1. Proportion of extended-spectrum beta-lactamase producing strains isolated from  
 326 urines according to age in ambulatory patients in 2013

327

Variable	Age group					<i>P</i> value*
	0-20	21-40	41-60	61-80	> 80	
<b><i>Escherichia coli</i></b>						
- Total (n=51463)	2.0	1.9	2.5	3.9	5.4	0.001
- Female (42839)	2.0	1.9	2.3	3.6	5.1	0.001
- Male (6733)	2.9	1.7	3.6	5.5	6.8	0.001
<b><i>Klebsiella pneumoniae</i></b>						
- Total (n=3495)	3.4	4.1	4.8	6.5	10.3	0.001
- Female (n=2753)	2.4	3.8	3.3	4.3	10.7	0.001
- Male (n=594)	NA	9.1	11.7	13.7	7.6	0.001

328 NA: the number of isolates was <30;

329 \* *P*-value: chi-square for trend

330

331

332

333 Table 2. Susceptibility (%) to the main antibiotics of strains isolated from urines in  
 334 ambulatory patients in 2013  
 335

Variable	Co-amox	Cefixime	Ciprofloxacin	Fosfomycin	Nitrofurantoin	Cotrimoxazole
<b><i>Escherichia coli</i> (n=51463)</b>						
Total	66.1	95.0	89.5	98.7	98.8	79.6
Gender						
- Female	66.9	95.4	90.3	98.7	98.9	80.0
- Male	61.6	92.8	84.4	98.6*	98.1	77.5
ESBL production						
- ESBL-negative isolates	67.6	98.0	91.0	98.9	98.9	80.8
- ESBL-positive isolates	22.7	4.0	44.0	93.7	95.4	47.5
<b><i>Klebsiella pneumoniae</i> (n=3495)</b>						
- Total	-	93.2	91.2	74.4	71.0	88.4

336 Co-amox: co-amoxiclav.

337 All differences between ESBL-positive and ESBL-negative isolates, between female and male  
 338 patients, and between total *E. coli* and *K. pneumoniae* isolates are statistically significant  
 339 ( $p < 0.001$ ) but for \*

The production of extended-spectrum beta-lactamase in Enterobacteriaceae has been associated with increased treatment failure and higher management costs.

The prevalence of extended-spectrum beta-lactamase producing *Escherichia coli* in urinary samples from outpatients has increased significantly in France to reach 3.3%.

The prevalence of extended-spectrum beta-lactamase producing *Klebsiella pneumoniae* in the outpatient setting is circa twice than for *Escherichia coli*

The prevalence of extended-spectrum beta-lactamase producing *Escherichia coli* in nursing homes is circa 4 times higher than in the outpatient setting.

The prevalence of extended-spectrum beta-lactamase producing *Escherichia coli* in urinary samples increases significantly with patient's age.